1-4 of 4
David Parry
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

Ryan Montano, Injae Chung, Kristen M. Garner, David Parry, Alan Eastman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 427–438.
https://doi.org/10.1158/1535-7163.MCT-11-0406
Published: 08 February 2012
View article titled, Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
Open the PDF for Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites in another window
Includes: Supplementary data
Journal Articles

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Frances Shanahan, Nicole Davis, Lorena Taricani, Derek Wiswell, Wolfgang Seghezzi, Ervin Penaflor, Bhagyashree Bhagwat, Wei Wang, Danling Gu, Yunsheng Hsieh, Suining Lee, Ming Liu, David Parry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (4): 591–602.
https://doi.org/10.1158/1535-7163.MCT-10-0928
Published: 06 April 2011
View article titled, Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Open the PDF for Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening in another window
Includes: Supplementary data
Journal Articles

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

David Parry, Timothy Guzi, Frances Shanahan, Nicole Davis, Deepa Prabhavalkar, Derek Wiswell, Wolfgang Seghezzi, Kamil Paruch, Michael P. Dwyer, Ronald Doll, Amin Nomeir, William Windsor, Thierry Fischmann, Yaolin Wang, Martin Oft, Taiying Chen, Paul Kirschmeier, Emma M. Lees
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (8): 2344–2353.
https://doi.org/10.1158/1535-7163.MCT-10-0324
Published: 09 August 2010
View article titled, Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Open the PDF for Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor in another window
Includes: Supplementary data
Journal Articles

A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a novel cyclin-dependent kinase inhibitor administered weekly in subjects with advanced malignancies.

Rajat Bannerji, Marc Saltzman, Mitchell Rosenberg, Karen Small, Stuart Black, Paul Kirschmeier, Paul Statkevich, Malaz Abutarif, David Parry, Siu-Long Yao, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A117.
Published: 01 November 2007
View article titled, A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a novel cyclin-dependent kinase inhibitor administered weekly in subjects with advanced malignancies.